|
KMID : 0191120150300020167
|
|
Journal of Korean Medical Science
2015 Volume.30 No. 2 p.167 ~ p.172
|
|
|
Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels
|
|
Jeong In-A
Park Jong-Sun
Cho Young-Jae
Yoon Ho-Il
Song Jung-Han
Lee Choon-Taek
Lee Jae-Ho
|
|
|
Abstract
|
|
|
|
The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication. Anti-TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti-TB drug levels and other clinical factors were compared between the hepatotoxicity and non-hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity, 12 showed anti-TB DIH. Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti-TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti-TB DIH in patients being treated with the currently recommended doses of first-line anti-TB treatment drugs.
|
|
|
KEYWORD
|
|
|
Therapeutic Drug Monitoring, Hepatotoxicity, Tuberculosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|